{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:36:03Z","timestamp":1793900163041,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003757","name":"Foundation for the Advancement in Research in Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003757","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1136\/ard-2024-226113","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T17:20:36Z","timestamp":1729185636000},"page":"504-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Beh\u00e7et's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-9611","authenticated-orcid":false,"given":"Rosaria","family":"Talarico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-8321","authenticated-orcid":false,"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1126-8315","authenticated-orcid":false,"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-0576","authenticated-orcid":false,"given":"Alberto","family":"Floris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Di Cianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Chiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Marinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Del Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Figus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Posarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Vagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Andreozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Lorenzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Turchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Della Casa Alberighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-4574","authenticated-orcid":false,"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-226113_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/BOR.0000000000000666","article-title":"Management of Beh\u00e7et syndrome","volume":"32","author":"Yazici","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard-2024-226113_bib2","first-page":"1945","article-title":"Beh\u00e7et's syndrome: one year in review 2023","volume":"41","author":"Hatemi","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2024-226113_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ncprheum0436","article-title":"Beh\u00e7et's syndrome: disease manifestations, management, and advances in treatment","volume":"3","author":"Yazici","year":"2007","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-226113_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","article-title":"Beh\u00e7et syndrome: a contemporary view","volume":"14","author":"Yazici","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-226113_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001192","article-title":"Development and preliminary validation of the Beh\u00e7et's syndrome Overall Damage Index (BODI)","volume":"6","author":"Piga","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-226113_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13075-022-02947-y","article-title":"Accrual of organ damage in Beh\u00e7et's syndrome: trajectory, associated factors, and impact on patients' quality of life over a 2-year prospective follow-up study","volume":"24","author":"Floris","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-226113_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10198-023-01593-8","article-title":"A cost-of-illness study of Beh\u00e7et syndrome in Italy","volume":"25","author":"Lorenzoni","year":"2024","journal-title":"Eur J Health Econ"},{"key":"10.1136\/ard-2024-226113_bib8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11739-017-1691-z","article-title":"Quality of life impairment in Beh\u00e7et's disease and relationship with disease activity: a prospective study","volume":"12","author":"Fabiani","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1136\/ard-2024-226113_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-023-02668-8","article-title":"Exploring disease perception in Beh\u00e7et's syndrome: combining a quantitative and a qualitative study based on a narrative medicine approach","volume":"18","author":"Marinello","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1136\/ard-2024-226113_bib10","first-page":"125","article-title":"Beh\u00e7et's syndrome and psychiatric involvement: is it a primary or secondary feature of the disease?","volume":"36","author":"Talarico","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2024-226113_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40263-015-0228-0","article-title":"Epidemiology and management of neuropsychiatric disorders in Beh\u00e7et's syndrome","volume":"29","author":"Talarico","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1136\/ard-2024-226113_bib12","first-page":"43","article-title":"Beh\u00e7et's syndrome and health-related quality of life: influence of symptoms, lifestyle and employment status","volume":"35","author":"Senusi","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2024-226113_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","article-title":"Vascular Beh\u00e7et syndrome: from pathogenesis to treatment","volume":"19","author":"Bettiol","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-226113_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight threatening panuveitis in Beh\u00e7et's disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-226113_bib15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight threatening ocular inflammation in Adamantiades-Beh\u00e7et disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2024-226113_bib16","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et's disease: an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-226113_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/1744666X.2023.2174103","article-title":"Comparing biologic options for the management of Behcet's disease-related uveitis","volume":"19","author":"Vitale","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1136\/ard-2024-226113_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab Treatment for Ocular and Extraocular Manifestations of Beh\u00e7et's Disease","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"10.1136\/ard-2024-226113_bib19","first-page":"41","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatology (Sunnyvale)"},{"key":"10.1136\/ard-2024-226113_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/09273948.2022.2157288","article-title":"Efficacy and Safety of Adalimumab in Patients with Beh\u00e7et Uveitis: A Systematic Review and Meta-Analysis","author":"Sener","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1136\/ard-2024-226113_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109242","article-title":"Long-term data on efficacy and safety of adalimumab in Beh\u00e7et's disease","volume":"247","author":"Van der Houwen","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1136\/ard-2024-226113_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109682","article-title":"Infliximab for vascular involvement in Beh\u00e7et's syndrome","volume":"253","author":"Hatemi","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1136\/ard-2024-226113_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","article-title":"Ten-Year Retention Rate of Infliximab in Patients with Beh\u00e7et's Disease-Related Uveitis","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1136\/ard-2024-226113_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231169895","article-title":"The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Beh\u00e7et's disease: a systematic review and meta-analysis","volume":"51","author":"Mohammed","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1136\/ard-2024-226113_bib25","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/AOG.0b013e3181d9d421","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"115","author":"Schulz","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ard-2024-226113_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152153","article-title":"Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients","volume":"58","author":"Barroso-Garc\u00eda","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2024-226113_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: Multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2024-226113_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/09273948.2020.1791346","article-title":"Anti-TNF-\u03b1 Therapy for Refractory Uveitis Associated with Beh\u00e7et's Syndrome and Sarcoidosis: A Single Center Study of 131 Patients","volume":"30","author":"Kunimi","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1136\/ard-2024-226113_bib29","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to beh\u00e7et's disease: National multicenter study of 177 cases","volume":"77","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-226113_bib30","first-page":"1560","article-title":"Assessing quality of life in Beh\u00e7et's disease: a systematic review","volume":"40","author":"Mastrolia","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2024-226113_bib31","author":"Gaggiano"},{"key":"10.1136\/ard-2024-226113_bib32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","article-title":"Beh\u00e7et's syndrome","volume":"403","author":"Emmi","year":"2024","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-226113_bib33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s13023-021-02070-2","article-title":"Being a caregiver of a Beh\u00e7et's syndrome patient: challenges and perspectives during a complex journey","volume":"16","author":"Talarico","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1136\/ard-2024-226113_bib34","article-title":"Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Beh\u00e7et's Syndrome","volume":"8","author":"Marinello","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1136\/ard-2024-226113_bib35","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/acr.24511","article-title":"Outcome Measures in Rheumatology Beh\u00e7et's Syndrome Working Group. Core Set of Domains for Outcome Measures in Beh\u00e7et'sSyndrome","volume":"74","author":"Hatemi","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-226113_bib36","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-226113_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109186","article-title":"Treat to target in Behcet's disease: Should we follow the paradigm of other systemic rheumatic diseases?","volume":"246","author":"Fragoulis","year":"2023","journal-title":"Clin Immunol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724005739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724005739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-226113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:14:56Z","timestamp":1750896896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724005739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0003496724005739"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-226113","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Beh\u00e7et's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-226113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}